Dr Daniel Tillett joins Simble Solutions to drive growth of ESG technologies
Prior to joining Simble Solutions’ board, Dr Daniel Tillett undertook due diligence and invested his own money to hold 10% of the entity.
Race Oncology (ASX: RAC) executive director and entrepreneur Dr Daniel Tillett has joined smart energy software as a service company Simble Solutions (ASX: SIS) to help drive commercialisation of its CarbonView and SimbleSense ESG (environmental, social and governance) technologies.
Dr Tillett is currently chief scientific officer and executive director of Race as well as the founder of chief executive officer of private Australian company Nucleics.
Nucleics produces and sells “world-leading” DNA sequencing software to the genomics sectors.
According to Simble, Nucleics SaaS genomics tools are now used at more than 250 companies and institutions across 30 countries.
Over at Race, Dr Tillett has been instrumental in turning the company from a $5 million market cap in 2019 to a market cap of over $500 million in 2022.
He is also Race’s largest shareholder and cornerstoned a capital raising in August 2019.
ESG critical to Australia’s future
Prior to joining Simble, Dr Tillett undertook due diligence and now owns about 32.8 million shares in the entity – representing almost 10% of its issued capital.
He also has 14.9 million listed and unlisted Simble options.
Dr Tillett said ESG was critical to Australia’s future and that he believes Simble can play a major role in the nation’s journey to achieving net zero.
Simble has developed software focused on energy intelligence and business productivity.
Its energy business division includes the SimbleSense and CarbonView software platforms.
SimbleSense combines hardware and software to visualise, control and monetise energy systems, while CarbonView is a carbon and sustainability reporting platform that allows companies to measure and reduce carbon emissions while meeting reporting obligations.
Simble chairman Ben Loiterton said he was certain Dr Tillett would make a “great contribution” to the company.
“Outside of his commercial roles, Daniel is a prominent investor, who invested in Simble after doing his own substantial due diligence on our products and market potential.”
“We welcome his expertise and interest in the work that Simble is doing to commercialise CarbonView and SimbleSense,” Mr Loiterton said.
Dr Tillett will not receive board fees in cash. Instead, he will be paid in options – 12 million in the first year of his appointment.
The options will have a $0.04 strike price, and one year expiry from the date of Dr Tillett’s appointment.